Items tagged with Treatment
Consortium of X-Chem, Harvard T.H. Chan School of Public Health and other leading academic institutions wins research award from the Department of Defense (post)
– Funding of $9.9 million by Department of Defense, Congressionally Directed Medical Research Programs to discover new treatments for TB
– Collaboration leverages unique genetic expertise and X-Chem’s proprietary DEXTM Platform to identify novel drugs against the deadly infectious disease
Russian Federation: TB treatments yield promising results in the Chechen Republic (post)
The first new drugs to be developed in 50 years were the last chance for some people with extensively drug-resistant tuberculosis (XDR-TB) in the Chechen Republic of the Russian Federation. In 2015, MSF’s Maria Borshova spoke to patients who had just started their new two-year-long treatments. She recently met them again.
Joint statement on STREAM Stage 1 MDR-TB clinical trial results (post)
Partners In Health (PIH), Interactive Research and Development (IRD) and the Zero TB Initiative (ZTBI) welcome the release of the interim results from the STREAM Stage 1 clinical trial. This is the first clinical trial of a new treatment regimen for multidrug-resistant tuberculosis (MDR-TB), and we congratulate the investigators for successfully conducting it. Unfortunately, we have noticed much confusion about the results of this clinical trial, both in the lay press and in the countries in which we work.
New TB drug making its way to India and Russia (post)
TOKYO -- With tuberculosis killing 1.67 million people every year, Otsuka Pharmaceutical is expediting deliveries of a new drug called Delamanid to India and other developing countries that are desperate for a cure.
Appeal from a TB survivor from Hungary (post)
Marta is a lung TB survivor from Hungary undergone TB treatment in 1959. She would like to share her experience and get in touch with other TB survivors around her age. Please read Marta’s appeal below and consider getting back to her.
Child-friendly TB FDCs: both intensive and continuation phase are now WHO prequalified (post)
The dispersible child-friendly TB fixed-dose combinations (FDCs) produced by Macleods Pharmaceuticals Ltd. have both received WHO prequalification (PQ):
TB drugs work better with vitamin C (post)
Washington, DC – January 3, 2018 – Studies in mice and in tissue cultures suggest that giving vitamin C with tuberculosis drugs could reduce the unusually long time it takes these drugs to eradicate this pathogen. The research is published in Antimicrobial Agents and Chemotherapy, a journal of the American Society for Microbiology.
Could vitamin C help fight TB? (post)
A new study suggests that a low-cost nutrient could help drugs fight tuberculosis more effectively.
Have your say! Survey on drug-resistant TB treatment options (post)
In December 2017, Treatment Action Group (TAG), ACTION and the Drug-Resistant TB Treatment Scale-up Action Team (DR-TB STAT) conducted a webinar on the results of two phase III trials for treating rifampicin-resistant TB.
Survival outcomes improved with concurrent treatment for multidrug-resistant TB and HIV (post)
Treatment of multidrug-resistant tuberculosis (TB) has comparable efficacy and survival rates in patients infected with HIV and not uninfected with HIV when patients with HIV are given antiretroviral therapy, according to the results of recent research published in Clinical Infectious Diseases.
Page 36 of 108 · Total posts: 0
←First 35 36 37 Last→